News Snapshot:
AstraZeneca has entered into an agreement with Shenzhen Kangtai Biological Products to manufacture and supply its coronavirus vaccine candidate, AZD1222, in mainland China. Under the terms of the exclusive cooperation agreement, Shengzhen Kangtai Bio commits to ensure annual production capacity of at least 100 million doses of AstraZeneca ( AZN ) potential vaccine AZD1222 by the end of this year. To meet the needs of the Chinese market, the Chinese vaccine maker needs to boost capacity to at least 200 million doses by the end of 2021, according to the agreement. The two partners said that they will explore the...
